Bayer treatment for systemic sclerosis receives FDA orphan designation According to a post on the FDA's website, Bayer's Adempas for the treatment of systemic sclerosis was granted orphan designation. Reference Link
Compugen achieves second preclinical milestone under Bayer cancer collaboration Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.